<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473029</url>
  </required_header>
  <id_info>
    <org_study_id>GEL_2014_01</org_study_id>
    <nct_id>NCT02473029</nct_id>
  </id_info>
  <brief_title>Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease</brief_title>
  <acronym>HORTIM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at measuring the sensitivity and specificity of a series of imaging signs
      (recorded by magnetic resonance angiography, vascular tomodensitometry, vascular
      ultrasonography, retina angiography and retina optic coherence tomography) for the diagnosis
      of Horton disease, the gold standard being the result of temporal artery biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI angiography mural inflammation</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence of signs of artery mural inflammation in T1 sequence of MRI angiography</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Horton Disease</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vascular tomodensitometry</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance angiography</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vascular ultrasonography</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retinal angiography</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retinal optical coherence tomography</intervention_name>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the Fondation Ophtalmologique Adolphe de Rothschild with a suspected
        Horton disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the Fondation Ophtalmologique Adolphe de Rothschild and suspected
             to suffer from Horton disease, based on the presence of 3 or more major criteria, or 2
             major criteria and at least one minor criteria.

        Major criteria : Age &gt; 50 ans ; headache ; intermittent jaw or tongue pain ; visual
        impairment ; ESR &gt; 50 mm at 1h and/or CRP &gt; 8mg/l.

        Minor criteria: temporal artery or scalp tenderness ; facial pain or tenderness ; fever
        &gt;38Â°C, weight loss &gt;10%, anorexia, fatigue.

        Exclusion Criteria:

          -  Autoimmune disease

          -  Active infectious condition

          -  Malignant disease

          -  Condition counterindicating one or several of the protocol's imaging procedures :
             allergy to iodine and/or renal insufficiency and/or claustrophobia and/or metallic
             foreign body...
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Herve Picard, MD MSc</last_name>
    <phone>(+33) 1 48 03 64 54</phone>
    <email>hpicard@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Salomon, MD PhD</last_name>
    <phone>(+33) 1 48 03 64 31</phone>
    <email>lsalomon@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rotchschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Picard, MD MSc</last_name>
      <phone>(+33) 1 48 03 64 54</phone>
      <email>hpicard@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Salomon, MD PhD</last_name>
      <phone>(+33) 1 48 03 64 31</phone>
      <email>lsalomon@for.paris</email>
    </contact_backup>
    <investigator>
      <last_name>Gaelle Clavel-Refregiers, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

